Similar articles

• The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.

  [No authors listed] [No authors listed] Prescrire Int. 2015 Feb;24(157):50-4. Prescrire Int. 2015. PMID: 25802924 Review.
• Encouraging spontaneous reporting of adverse effects.

  [No authors listed] [No authors listed] Prescrire Int. 2015 Feb;24(157):53. Prescrire Int. 2015. PMID: 25802925
• EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.

  Francescon S, Fornasier G, Baldo P. Francescon S, et al. Int J Clin Pharm. 2018 Aug;40(4):778-782. doi: 10.1007/s11096-018-0709-6. Epub 2018 Aug 9. Int J Clin Pharm. 2018. PMID: 30094558 Free PMC article.
• Is pharmacovigilance of biologicals cost-effective?

  Claus B. Claus B. Int J Clin Pharm. 2018 Aug;40(4):787-789. doi: 10.1007/s11096-018-0695-8. Epub 2018 Jul 26. Int J Clin Pharm. 2018. PMID: 30051230
• [Adverse drug reaction - Definitions, risk factors and pharmacovigilance].

  Krähenbühl S. Krähenbühl S. Ther Umsch. 2015 Dec;72(11-12):669-71. doi: 10.1024/0040-5930/a000735. Ther Umsch. 2015. PMID: 26654809 Review. German.